Scholarlink

<p>Vaccination remains the most promising long-term strategy for controlling leishmaniasis, as individuals who recover from primary infection generally develop protective immunity. However, no vaccine is currently available for human use. In this study, we identified two immunogenic proteins that may account for the protective effect previously observed with the <i>Leishmania amazonensis</i> microsomal fraction (MicF), which confers protection in murine models. Both proteins were expressed in <i>Escherichia coli</i> and used to immunize mice, eliciting specific humoral responses and promoting elevated production of Th1-associated cytokines. Considering the well-documented difficulty in inducing effective immunity against <i>L. amazonensis</i>, a species associated with diffuse cutaneous leishmaniasis and marked host anergy, the identification of these proteins as strong immunogens is noteworthy. Collectively, our findings provide preliminary evidence supporting the <i>Leishmania</i> homolog of receptors for activated C kinase (LACK) and phosphoenolpyruvate carboxykinase (PEPCK) as potential vaccine candidates against <i>L. amazonensis</i>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antigenic profiling of Leishmania amazonensis microsomal fraction to support vaccine development

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月20日

查看全文
  • Juan Matheus Pereira Fernandes,
  • Edlainne Pinheiro Ferreira Sena,
  • Marcos Gustavo Araujo Schwarz,
  • Meydson Benjamim Carvalho Corrêa,
  • Daiana de Jesus Hardoim,
  • Katia Carneiro,
  • Luiz Ney d’ Escoffier,
  • Celesta da Silva Freitas de Souza,
  • Tânia Zaverucha do Valle,
  • Kátia da Silva Calabrese

摘要

Vaccination remains the most promising long-term strategy for controlling leishmaniasis, as individuals who recover from primary infection generally develop protective immunity. However, no vaccine is currently available for human use. In this study, we identified two immunogenic proteins that may account for the protective effect previously observed with the Leishmania amazonensis microsomal fraction (MicF), which confers protection in murine models. Both proteins were expressed in Escherichia coli and used to immunize mice, eliciting specific humoral responses and promoting elevated production of Th1-associated cytokines. Considering the well-documented difficulty in inducing effective immunity against L. amazonensis, a species associated with diffuse cutaneous leishmaniasis and marked host anergy, the identification of these proteins as strong immunogens is noteworthy. Collectively, our findings provide preliminary evidence supporting the Leishmania homolog of receptors for activated C kinase (LACK) and phosphoenolpyruvate carboxykinase (PEPCK) as potential vaccine candidates against L. amazonensis.